This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

The 21st International Symposium of the Princess Takamatsu Cancer Resarch Fund covered advances in chemical carcinogenesis and cancer chemotherapy. It notes that humans are continuously exposed to carcinogens, so the amount of carcinogenic xenobiotics and the human response to them is important.

Written by leading research scientists, this book integrates current knowledge of toxicology and human health through coverage of environmental toxicants, genetic / epigenetic mechanisms, and carcinogenicity. Provides information on lifestyle choices that can reduce cancer risk Offers a systematic approach to identify mutagenic, developmental and reproductive toxicants Helps readers develop new animal models and tests to assess toxic impacts of mutation and cancer on human health Explains specific cellular and molecular targets of known toxicants operating through genetic and epigenetic mechanisms

Xenobiotics in Chemical Carcinogenesis: Translational Aspects in Toxicology covers the translational toxicology of xenobiotics substances in carcinogenesis by explaining the toxicokinetic and toxicodynamic, toxicogenomic, biotransformation, and resistance mechanisms in the human body. The book begins with a historical review and link to future prospects for chemical carcinogenesis. It discusses major environmental xenobiotics and their risks in inducing cancer, along with content on toxic xenobiotics and their routes of exposure in humans, the role of xenobiotic metabolism in carcinogenesis, and the toxicokinetic and toxicodynamic of xenobiotics in cancer development. Lastly, the book explores current achievements such as using toxicogenomics for predicting the carcinogenicity of xenobiotic substances and the challenges posed by carcinogenic xenobiotic substances when examining preventive methods, diagnosis, and the development of anticancer drugs for specific toxicants. - Covers the exposure and transmission of various toxic xenobiotics substances, including nanomaterials, to humans and their interaction with specific tissues in precipitating the development of cancers - Unravels the toxicokinetic and toxicodynamic processes of toxic xenobiotics in bioaccumulation - Examines the genetic aberrations in cancer genomes by genetic-environmental interactions in carcinogenesis - Explains the biotransformation mechanisms of toxic xenobiotics by gut microbes in humans

A practice-oriented desktop reference for medical professionals, toxicologists and pharmaceutical researchers, this handbook provides systematic coverage of the metabolic pathways of all major classes of xenobiotics in the human body. The first part comprehensively reviews the main enzyme systems involved in biotransformation and how they are orchestrated in the body, while parts two to four cover the three main classes of xenobiotics: drugs, natural products, environmental pollutants. The part on drugs includes more than 300 substances from five major therapeutic groups (central nervous system, cardiovascular system, cancer, infection, and pain) as well as most drugs of abuse including nicotine, alcohol and "designer" drugs. Selected, well-documented case studies from the most important xenobiotics classes illustrate general principles of metabolism, making this equally useful for teaching courses on pharmacology, drug metabolism or molecular toxicology. Of particular interest, and unique to this volume is the inclusion of a wide range of additional xenobiotic compounds, including food supplements, herbal preparations, and agrochemicals.

Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read. Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field.